US Edition
Published • loading... • Updated
New Once Weekly Investigational Oral Regimen Shows Strong 48 Week Results, Highlighting the Need for Easier HIV Treatment Options
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
New Once Weekly Investigational Oral Regimen Shows Strong 48 Week Results, Highlighting the Need for Easier HIV Treatment Options
A once‑weekly, all‑oral combination of islatravir (ISL) and lenacapavir (LEN) maintains high levels of virologic suppression through 48 weeks in adults living with HIV.
·Charlottesville, United States
Read Full ArticleCoverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
